Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SynAct Pharma ABOSTO:SYNACT +2.47%27 Equity-to-Asset is 0.82 as of Jun. 2026, which is 5% above its 10-year median of 0.78. GuruFocus rates OSTO:SYNACT with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, SynAct Pharma AB ranks better than 69.09% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. SynAct Pharma AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr171.67 Mil. SynAct Pharma AB's Total Assets for the quarter that ended in Jun. 2026 was kr208.24 Mil.
The historical rank and industry rank for SynAct Pharma AB's Equity-to-Asset or its related term are showing as below:
OSTO:SYNACT'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.33 Med: 0.78 Max: 0.98
Current: 0.82
During the past 10 years, the highest Equity to Asset Ratio of SynAct Pharma AB was 0.98. The lowest was -0.33. And the median was 0.78.
OSTO:SYNACT's Equity-to-Asset is ranked better than 69.09% of 1414
companies
in the Biotechnology industry
Industry Median: 0.69
vs OSTO:SYNACT: 0.82
SynAct Pharma AB (OSTO:SYNACT) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
SynAct Pharma AB Equity-to-Asset Related Terms
SynAct Pharma AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for SynAct Pharma AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SYNACT vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, SynAct Pharma AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SynAct Pharma AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where SynAct Pharma AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
SynAct Pharma AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SynAct Pharma AB (OSTO:SYNACT) has a Equity-to-Asset of 0.82 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on SynAct Pharma AB and its competitors. This is near median its historical median of 0.78. According to the industry distribution chart, SynAct Pharma AB ranks #437 out of 1414 companies in the Biotechnology industry, placing it in the top 30.9%.
Is SynAct Pharma AB's Equity-to-Asset too high?
SynAct Pharma AB's current Equity-to-Asset of 0.82 is near median its 10-year median of 0.78. The Biotechnology industry median Equity-to-Asset is 0.69. SynAct Pharma AB's value of 0.82 is 18.8% above this industry median. Based on the distribution chart, SynAct Pharma AB ranks #437 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, SynAct Pharma AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SynAct Pharma AB ranks #437 out of 1414 companies for Equity-to-Asset. This puts SynAct Pharma AB in the upper half of its industry. The industry median Equity-to-Asset is 0.69. SynAct Pharma AB's value of 0.82 is 18.8% above this benchmark. While the company's 10-year median is 0.78 vs. the industry median of 0.69, SynAct Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SynAct Pharma AB's current Equity-to-Asset of 0.82 is 18.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on SynAct Pharma AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SynAct Pharma AB's current Equity-to-Asset is 0.82, which is near median its own 10-year median of 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current Equity-to-Asset of 0.82. The current Equity-to-Asset is 0.82, which is near median its 10-year median of 0.78 and 18.8% above the Biotechnology industry median of 0.69. SynAct Pharma AB's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current Equity-to-Asset is 0.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
27GF Score
Get the complete analysis for OSTO:SYNACT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SYNACT has been successfully added to your 
